Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fosaprepitant dimeglumine
Drug ID BADD_D00963
Description Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Indications and Usage For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB06717
KEGG ID D06597
MeSH ID C579707
PubChem ID 136086851
TTD Drug ID Not Available
NDC Product Code 65085-0060; 66039-904; 0781-3484; 14501-0064; 65977-0080; 16714-248; 0006-3061; 82238-018; 70447-0001; 0143-9428; 76339-141; 0338-0008; 68001-523; 71731-5111; 61662-0007; 59651-111; 31722-165; 0143-9384; 67184-0540; 70860-783; 63552-011; 55150-299; 52133-0045
UNII D35FM8T64X
Synonyms fosaprepitant | Emend for injection | fosaprepitant dimeglumine | L 785,298 | L785,298 | L-785,298
Chemical Information
Molecular Formula C30H39F7N5O11P
CAS Registry Number 265121-04-8
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C( C=C4)F.CNCC(C(C(C(CO)O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008--
Type I hypersensitivity10.01.03.006--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Visual acuity reduced06.02.10.012; 17.17.01.011--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Wound dehiscence12.02.05.003--
Infusion site erythema08.02.05.008; 23.03.06.016; 12.07.05.009--Not Available
Subileus07.13.01.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Epigastric discomfort07.01.02.004--Not Available
Infusion site induration12.07.05.010; 08.02.05.009--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site pruritus12.07.05.005; 08.02.05.004; 23.03.12.006--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Staphylococcal infection11.02.05.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages